Medtrum, a global diabetes technology company, announced further progress toward the German launch of its 300-unit (300U) tubeless patch pump, following its presentation at DDG 2026 in Berlin and inclusion in Germany's statutory health insurance medical aids directory.

For people with diabetes who require larger daily insulin doses, reservoir capacity can influence how frequently a patch pump needs to be replaced and how easily therapy fits into daily routines. Medtrum's 300U pump offers 50 per cent greater reservoir capacity than commonly used 200-unit patch pumps while maintaining a discreet, tubeless and body-worn design.

Already available in selected international markets, the 300U pump will further expand Medtrum's tubeless insulin delivery portfolio in Europe. At DDG 2026, the pump was central to Medtrum's exhibition theme, "Medtrum macht mehr möglich" ("Medtrum makes more possible"). The 300U pump has been listed in the directory under its own Hilfsmittelnummer, a dedicated product code enabling access through Germany's statutory reimbursement system.

"Germany is one of Europe's leading diabetes technology markets, with strong clinical adoption, an established reimbursement framework and continued innovation," said Scott Yang, founder and CEO of Medtrum. "The planned introduction of our 300U patch pump reflects our commitment to patient-centered treatment options. By strengthening our direct commercial operations, building partnerships and generating clinical evidence, we aim to support broader patient access and sustainable growth across Europe."